Systemic immune-inflammation index combined with prognostic nutritional index for predicting cholangiocarcinoma PFS

SII-PNI (integrating inflammation and nutrition) effectively predicts CCA's PFS (HR = 1.51, p < 0.005), outperforming conventional biomarkers like CA19-9. Its cost-effectiveness supports CCA risk stratification. However, SII-PNI-based dynamic treatment response monitoring is unvalidated (retrospective limitation) and needs prospective trials; no intensified treatment recommendations are made.